Business Description
Crism Therapeutics Corp
ISIN : VGG042401007
Total Employee Number:
1Description
Crism Therapeutics Corp has developed a drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs. Its product ChemoSeed which is in its clinical trial phase, can be implanted directly into the tumour or the resection margin following the removal of a tumour. The company also provides consultancy and formulation services to its clients assisting them with pharmaceutical formulation and development.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.76 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 12.85 | |||||
Beneish M-Score | -1.47 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 51.1 | |||||
3-Year EPS without NRI Growth Rate | 44 | |||||
3-Year FCF Growth Rate | 46.3 | |||||
3-Year Book Growth Rate | -74.1 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 5.93 | |||||
9-Day RSI | 16.86 | |||||
14-Day RSI | 23.72 | |||||
3-1 Month Momentum % | -8.51 | |||||
6-1 Month Momentum % | 7.5 | |||||
12-1 Month Momentum % | -6.52 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.65 | |||||
Quick Ratio | 3.65 | |||||
Cash Ratio | 0.82 | |||||
Days Sales Outstanding | 175.2 | |||||
Days Payable | 4953.57 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -55.9 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 72 | |||||
Operating Margin % | -5952 | |||||
Net Margin % | -6096 | |||||
EBITDA Margin % | -5888 | |||||
FCF Margin % | -864.94 | |||||
OCF Margin % | -851.52 | |||||
ROE % | -94.17 | |||||
ROA % | -76.56 | |||||
ROIC % | -256.99 | |||||
3-Year ROIIC % | -2.42 | |||||
ROC (Joel Greenblatt) % | -2209.9 | |||||
ROCE % | -91.95 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 97.5 | |||||
PB Ratio | 2.95 | |||||
Price-to-Tangible-Book | 3.25 | |||||
EV-to-EBIT | -4.46 | |||||
EV-to-EBITDA | -4.51 | |||||
EV-to-Revenue | 265.48 | |||||
EV-to-FCF | -4.67 | |||||
| Price-to-Net-Current-Asset-Value | 3.25 | |||||
| Price-to-Net-Cash | 3.25 | |||||
Earnings Yield (Greenblatt) % | -22.42 | |||||
FCF Yield % | -17.96 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Crism Therapeutics Corp Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil £) | 0.231 | ||
| EPS (TTM) (£) | -0.051 | ||
| Beta | 2.7336 | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 66.3 | ||
| 14-Day RSI | 23.72 | ||
| 14-Day ATR (£) | 0.012346 | ||
| 20-Day SMA (£) | 0.1055 | ||
| 12-1 Month Momentum % | -6.52 | ||
| 52-Week Range (£) | 0.08 - 0.185 | ||
| Shares Outstanding (Mil) | 79.19 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Crism Therapeutics Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Crism Therapeutics Corp Stock Events
| Event | Date | Price (£) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2026 | 2026-09-16 11:00 | In 78 days | ||
| Second quarter earnings results for 2026 | 2026-09-15 | In 76 days | ||
| General meeting for 2025 | 2026-08-26 | In 56 days | ||
| Annual report for 2025 | 2026-06-26 | 0.10 (-2.44%) | ||
| Fourth quarter earnings results for 2025 | 2026-06-26 | 0.10 (-2.44%) | ||
| Second quarter earnings conference call for 2025 | 2025-09-19 12:00 | 0.10 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-09-19 | 0.10 (+0.00%) | ||
| Second quarter earnings conference call for 2025 | 2025-09-16 11:00 | 0.10 (+14.71%) | ||
| Second quarter earnings results for 2025 | 2025-09-15 | 0.08 (-1.47%) | ||
| General meeting for 2024 | 2025-08-26 10:00 | 0.11 (+0.00%) |
Show
Entries
Crism Therapeutics Corp Frequently Asked Questions
What is Crism Therapeutics Corp(LSE:CRTX)'s stock price today?
The current price of LSE:CRTX is £0.10. The 52 week high of LSE:CRTX is £0.19 and 52 week low is £0.08.
When is next earnings date of Crism Therapeutics Corp(LSE:CRTX)?
The next earnings date of Crism Therapeutics Corp(LSE:CRTX) is 2026-09-15 Est..
Does Crism Therapeutics Corp(LSE:CRTX) pay dividends? If so, how much?
Crism Therapeutics Corp(LSE:CRTX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Crism Therapeutics Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers